PMA supplement
P230030 S017: FARAPULSE™ Pulsed Field Ablation System (FARAPULSE)
FDA PMA supplement · 30-Day Notice · Farapulse, Inc.
Key facts
| Original PMA | P230030 |
|---|---|
| Supplement number | S017 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | FARAPULSE™ Pulsed Field Ablation System (FARAPULSE) |
| Generic name | Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation |
| Applicant | Farapulse, Inc. |
| Product code | QZI |
| Received date | Dec 19, 2025 |
| Decision date | Jan 13, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: